COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,

COVID 补充材料 - 流感疫苗创新中心 (CIVICS) 项目的 A 部分，用于设计和评估创新型流感疫苗方法，

• 批准号: 10621132
• 负责人: TED ROSS
• 金额: $ 222.94万
• 依托单位: UNIVERSITY OF GEORGIA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-10 至 2023-05-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10621132
• 关键词: Animal Model; Animals; COVID-19 vaccine; Communicable Diseases; Contractor; Contracts; Coronavirus; Elderly; Human; Immune; Immune response; Immunity; Individual; Mucous Membrane; National Institute of Allergy and Infectious Disease; Recording of previous events; United States National Institutes of Health; Vaccinated; Vaccines; anti-influenza; coronavirus disease; design; high risk; high risk population; immunogenicity; influenza virus vaccine; innovation; next generation; novel vaccines; obese person; pregnant; programs; response; seasonal influenza; standard of care; universal influenza vaccine; universal vaccine; vaccine development; vaccine strategy

The objective of this contract program is to support improvements in the immunogenicity and durability of seasonal influenza vaccines, SARS-COV-2 vaccines and the development of innovative influenza vaccine approaches that provide robust, durable, broadly protective mucosal and systemic anti-influenza immunity (“universal influenza vaccines”) and other emerging or reemerging infectious diseases.

该合同计划的目的是支持季节性影响疫苗，SARS-COV-2疫苗的免疫原性和耐用性的改善，以及创新影响疫苗的开发，这些方法提供了可提供可靠，耐用，广泛保护的粘膜和全身性抗激素氮Immunoyoyches（“通用疫苗”（“通用疫苗”）和其他Emerering或Emerereging或Reereging或Reereging Infcections和Reemerging或Reereging Infcect。